ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Dianthus Therapeutics Inc

Dianthus Therapeutics Inc (DNTH)

21.75
0.25
( 1.16% )
Updated: 12:45:59

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
21.75
Bid
21.70
Ask
21.92
Volume
75,151
21.12 Day's Range 22.42
6.58 52 Week Range 33.77
Market Cap
Previous Close
21.50
Open
21.75
Last Trade
22
@
21.905
Last Trade Time
12:47:24
Financial Volume
$ 1,647,694
VWAP
21.9251
Average Volume (3m)
172,971
Shares Outstanding
14,817,762
Dividend Yield
-
PE Ratio
-7.48
Earnings Per Share (EPS)
-2.94
Revenue
2.83M
Net Profit
-43.56M

About Dianthus Therapeutics Inc

Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, and others. Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, and others.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Dianthus Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DNTH. The last closing price for Dianthus Therapeutics was $21.50. Over the last year, Dianthus Therapeutics shares have traded in a share price range of $ 6.58 to $ 33.77.

Dianthus Therapeutics currently has 14,817,762 shares outstanding. The market capitalization of Dianthus Therapeutics is $325.84 million. Dianthus Therapeutics has a price to earnings ratio (PE ratio) of -7.48.

DNTH Latest News

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of...

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) initiated in Q1’24 with top-line results anticipated in 2H’25 $389 million of pro forma cash, including $216 million of net proceeds...

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the...

Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

Top-line results from gMG MaGic trial anticipated in 2H 2025 Building a neuromuscular franchise with DNTH103 through additional planned Phase 2 trials in Multifocal Motor Neuropathy (MMN) and...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.56-6.6924066924123.3124.4319.7317467022.33154265CS
4-8.14-27.233188357329.8930.517519.7317167824.28387198CS
121.758.752033.7719.2517297125.61360903CS
269.7581.251233.776.5810317523.142466CS
5211.35109.13461538510.433.776.588724722.39752076CS
15611.35109.13461538510.433.776.588724722.39752076CS
26011.35109.13461538510.433.776.588724722.39752076CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CAUDCollective Audience Inc
$ 0.7327
(87.87%)
139.03M
DCPHDeciphera Pharmaceuticals Inc
$ 25.285
(72.59%)
39.68M
MULNMullen Automotive Inc
$ 4.47
(41.46%)
33.65M
HWHHWH International Inc
$ 2.52
(38.46%)
23.06M
BTOGBit Origin Ltd
$ 4.46
(34.34%)
396.42k
CLVRClever Leaves Holdings Inc
$ 1.59
(-61.31%)
615.22k
ADXNAddex Therapeutics Ltd
$ 8.00
(-50.31%)
123.03k
MFImF International Ltd
$ 1.5294
(-34.36%)
2.52M
TSDDGraniteShares ETF Trust GraniteShares
$ 17.00
(-31.73%)
1.16M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
$ 26.88
(-31.55%)
5.82M
TSLATesla Inc
$ 194.94
(15.84%)
163.83M
CAUDCollective Audience Inc
$ 0.7327
(87.87%)
139.03M
SINTSiNtx Technologies Inc
$ 0.0527
(30.45%)
138.53M
SOFISoFi Technologies Inc
$ 7.0899
(-9.91%)
112.19M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 9.42
(31.75%)
63.74M

Your Recent History

Delayed Upgrade Clock